FDA finds benzene contamination, Tronox to close a pigment plant, Sofinnova launches a European biotech fund, and more ...
The litany of big-ticket deals involving antibody-drug conjugates shows no sign of ending. In the latest recitation, Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-direct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback